Policy Brief: How the Supreme Court Patent Case Could Raise Drug Prices

11 Oct 2017
View Resource

With the majority of voters on both sides of the aisle saying Congress’s top priority should be lowering high drug costs, an upcoming U.S. Supreme Court case could significantly hamper the country’s ability to lower the price of medicine and assess and remove unmerited pharmaceutical patents. This policy brief examines the little-discussed health implications of Oil Energy States v. Greene’s Energy Group, which will address the constitutionality of the U.S. Patent and Trademark Office’s process to help make sure patents meet legal requirements.

Partner with us now to build
a more just and equitable
medicine system for all.